Results 51 to 60 of about 3,710 (152)

Riociguat (Adempas®) bei pulmonaler Hypertonie – genaue Diagnostik entscheidend

, 2016
Am 24.06.2016 veröffentlichte die Europäische Arzneimittelagentur (EMA) eine Mitteilung, nach der Riociguat (Adempas®) nicht bei Patienten mit pulmonaler Hypertonie wegen einer idiopathischen interstitiellen Pneumonie eingesetzt werden darf. Die RISE-IIP-
Mittmann, C.
core   +1 more source

Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis

, 2021
BACKGROUND: Riociguat is a first-in-class soluble guanylate cyclase stimulator for which preclinical data suggested improvements in cystic fibrosis transmembrane conductance regulator (CFTR) function.METHODS: This international, multicenter, two-part ...
Hoffmann, Anja, Bear, Christine E., Droebner, Karoline, Downey, Damian G; id_orcid, Willmann, Stefan, Rowe, Steven M, Nazareth, Dilip, Bear, Christine E, Rosenbluth, Daniel, Vermeulen, Francois, Downey, Damian G., Davies, Jane C, Derichs, Nico, Fajac, Isabelle, Jensen, Renee, Tullis, Elizabeth, Saunders, Clare, Kaiser, Andreas, Davies, Jane C., Sandner, Peter, Malfroot, Anne, Taylor-Cousar, Jennifer L, Saleh, Soundos, Ratjen, Felix, Solomon, George M, Taylor-Cousar, Jennifer L., Solomon, George M., Rowe, Steven M.   +27 more
core   +1 more source

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat

Терапевтический архив, 2020
Currently, treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is focused on three signaling pathways: the NO pathway, the endothelin pathway, and the prostacyclin pathway.
S. E. Gratsianskaya, Z. S. Valieva, T. V. Martynyuk   +2 more
doaj   +1 more source

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension [PDF]

, 2022
Pulmonary hypertension (PH), which includes pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is a progressive condition with significant morbidity and mortality due to right heart failure if left untreated.
Kenny, Marianne, Kenny, M., Clarke, Megan M., Pogue, Kristen T., Pogue, K.T., Clarke, M.M.   +5 more
core   +1 more source

Effects of riociguat on hemodynamics.

, 2013
(A) Systolic blood pressure data were obtained by using a LV-catheter during infarct size measurement in the acute model with 30 min ischaemia followed by 2 h reperfusion.
Axel Kretschmer (142870), Guido Buonincontri (503734), Adrian Carpenter (503738), Carmen Methner (503733), Chou-Hui Hu (503735), Johannes-Peter Stasch (142873), Ana Vujic (503736), Thomas Krieg (60638), Stephen Sawiak (503737)   +8 more
core   +1 more source

CLINICAL CASE: OPPORTUNITY OF THERAPY OPTIMIZATION DUE TO TRANSITIONING FROM SILDENAFIL TO RIOCIGUAT IN PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION

Евразийский Кардиологический Журнал, 2016
SUMMERY The patient with diagnosis of idiopathic pulmonary hypertension, functional class III (WHO) was treated by anticoagulants, diuretics. After 6 months of treatment with phosphodiesterase type 5-inhibitor sildenafil, there was observed the negative ...
I. N. Taran, V. M. Paramonov, Z. S. Valieva, M. A. Saidova, S. N. Nakonechnikov, T. V. Martynyuk, I. Ye. Chazova   +6 more
doaj   +1 more source

Phenotypic Clustering of Idiopathic Pulmonary Arterial Hypertension: Insights Into Pulmonary Vascular and Cardiometabolic Co‐Morbidity Trajectories

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Idiopathic pulmonary arterial hypertension (IPAH) exhibits significant clinical heterogeneity, necessitating a precision medicine approach. This study aimed to identify distinct IPAH phenotypes using machine learning‐based clustering and to evaluate their longitudinal therapeutic responses and long‐term survival.
Cihangir Kaymaz, Barkin Kultursay, Hacer Ceren Tokgoz, Seda Tanyeri, Cagdas Bulus, Berhan Keskin, Caglar Emre Cagliyan, Metehan Kibar, Can Erdem, Aziz Vezir, Ipek Akkus, Muhammet Bulut, Aykun Hakgor, Ibrahim Halil Tanboga, Nihal Ozdemir   +14 more
wiley   +1 more source

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Pulmonary Circulation, 2020
Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble ...
Raymond L. Benza, Paul A. Corris, Hossein-Ardeschir Ghofrani, Manreet Kanwar, Vallerie V. McLaughlin, Amresh Raina, Gérald Simonneau   +6 more
doaj   +1 more source

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics

Frontiers in Medicine, 2021
High-altitude pulmonary hypertension (HAPH) is a complication arising from an inability to acclimatize to high altitude and is associated with high morbidity and mortality.
Xiang Xu, Hanlu Li, Qingxia Wei, Xin Li, Xin Li, Yanying Shen, Ge Guo, Yibing Chen, Kunlun He, Kunlun He, Chunlei Liu, Chunlei Liu   +11 more
doaj   +1 more source